



13 May 2024

Repayment of Epsilon facility

SomnoMed Limited (**ASX "SOM"**) advises that as foreshadowed in the Prospectus accompanying the Company's recent Entitlement Offer, a portion of the proceeds from the Entitlement Offer (\$11.5 million) has been applied to paying out the entire balance of the Company's loan facility provided by Epsilon Direct Lending.

Authorised for release to the ASX by Terry Flitcroft, Company Secretary

About SomnoMed

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 885,000 patients in 28 countries. For further information, visit SomnoMed at <http://www.somnomed.com.au>

For personal use only